Gene Name,HGNC ID,MONDO Disease Name,MONDO ID,MOI,Report? ,Reporting Guidance,Internal Comments,,Danielle's Notes:,,Marilyn's notes
ABCD1,HGNC:61,adrenoleukodystrophy,"MONDO:0018544",XL,Yes,"Hemizygous P/LP variants in males are reportable, as are biallelic P/LP variants in females. If phase is unknown for two heterozygous P/LP variants, the variants are acceptable for return as SFs if the variants do not have prior evidence of existing in cis (on the same copy of the gene). Single heterozygous P/LP variants in females are not reportable as SFs. ",,,,,
ACTA2,HGNC:130,familial thoracic aortic aneurysm and aortic dissection,MONDO:0019625,AD,Yes,,,,,Missing from Disease Naming sheet but displayed on the website and not an Actionability synonym,
ACTC1,HGNC:143,arrhythmogenic right ventricular cardiomyopathy,MONDO:0016587,AD,NA,,,,Pending,Has a Yes? or No? in the Disease Naming sheet,
ACTC1,HGNC:143,"atrial septal defect, ostium secundum type",MONDO:0020434,,NA,,Missing dosage score,,,,
ACTC1,HGNC:143,dilated cardiomyopathy,MONDO:0005021,AD,Yes,,,,Note: MOI added if available as part of a curation on the website,,
ACTC1,HGNC:143,hypertrophic cardiomyopathy,MONDO:0005045,AD,Yes,,,,,,
ACTC1,HGNC:143,familial hypertrophic cardiomyopathy,MONDO:0024573,AD,Yes,,,,,,
ACVRL1,HGNC:175,"telangiectasia, hereditary hemorrhagic, type 2",MONDO:0010880,AD,Yes,,,,,,
APC,HGNC:583,classic or attenuated familial adenomatous polyposis,MONDO:0021057,AD,Yes,"P/LP variants associated with both classic and attenuated FAP are recommended for return as SFs. At this time, P/LP variants associated with gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) are not recommended for return as SFs as the actionability for this phenotype may be different than for FAP and has not yet been evaluated by the ACMG SF committee. In addition, GAPPS is caused by P/LP promoter variants which would only be detectable by genome, not exome sequencing (https://pubmed.ncbi.nlm.nih.gov/39039610/)",,,,,
APC,HGNC:583,familial adenomatous polyposis 1,MONDO:0021056,AD,Yes,"P/LP variants associated with both classic and attenuated FAP are recommended for return as SFs. At this time, P/LP variants associated with gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) are not recommended for return as SFs as the actionability for this phenotype may be different than for FAP and has not yet been evaluated by the ACMG SF committee. In addition, GAPPS is caused by P/LP promoter variants which would only be detectable by genome, not exome sequencing (https://pubmed.ncbi.nlm.nih.gov/39039610/)",,,,,
APC,HGNC:583,gastric adenocarcinoma and proximal polyposis of the stomach,MONDO:0017790,AD,No,"P/LP variants associated with both classic and attenuated FAP are recommended for return as SFs. At this time, P/LP variants associated with gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) are not recommended for return as SFs as the actionability for this phenotype may be different than for FAP and has not yet been evaluated by the ACMG SF committee. In addition, GAPPS is caused by P/LP promoter variants which would only be detectable by genome, not exome sequencing (https://pubmed.ncbi.nlm.nih.gov/39039610/)",,,,,
APOB,HGNC:603,familial hypobetalipoproteinemia 1,MONDO:0014252,SD,No,"Pathogenic missense variants in the LDL-receptor binding domain of apoB impair binding of LDL to the LDL receptor, causing hypercholesterolemia and premature coronary artery disease, the primary features of FH. In contrast, pathogenic variants resulting in reduced secretion of APOB (mainly nonsense and frameshift variants) cause familial hypobetalipoproteinemia, which is characterized by hypocholesterolemia and resistance to atherosclerosis. Therefore, only P/LP missense variants with documented association with hypercholesterolemia are reportable as SFs.",,,,,
APOB,HGNC:603,"hypercholesterolemia, autosomal dominant, type B",MONDO:0007751,AD,Yes,"Pathogenic missense variants in the LDL-receptor binding domain of apoB impair binding of LDL to the LDL receptor, causing hypercholesterolemia and premature coronary artery disease, the primary features of FH. In contrast, pathogenic variants resulting in reduced secretion of APOB (mainly nonsense and frameshift variants) cause familial hypobetalipoproteinemia, which is characterized by hypocholesterolemia and resistance to atherosclerosis. Therefore, only P/LP missense variants with documented association with hypercholesterolemia are reportable as SFs.",,,,,
ATP7B,HGNC:870,Wilson disease,MONDO:0010200,AR,Yes,"ATP7B is only reportable if there are biallelic P/LP variants. If phase is unknown for two heterozygous P/LP variants, the variants are acceptable for return if the variants do not have prior evidence of existing in cis (on the same copy of the gene).",,,,,
BAG3,HGNC:939,myofibrillar myopathy,MONDO:0018943,AD,Yes,,,,,,
BAG3,HGNC:939,dilated cardiomyopathy,MONDO:0005021,AD,Yes,,,,,,
BAG3,HGNC:939,dilated cardiomyopathy 1HH,MONDO:0013479,AD,Yes,,,,,,
BMPR1A,HGNC:1076,pulmonary arterial hypertension,MONDO:0015924,Other,NA,,,,,,
BMPR1A,HGNC:1076,juvenile polyposis syndrome,MONDO:0017380,AD,Yes,,,,,,
BRCA1,HGNC:1100,BRCA1-related cancer predisposition,MONDO:0700268,AD,Yes,"The pathogenic mechanism for both hereditary breast cancer and Fanconi anemia is the same (loss-of-function), with single heterozygous variants causing breast cancer risk and biallelic variants causing Fanconi anemia. Therefore, P/LP variants that have been identified for either condition are reportable as SFs in the heterozygous or biallelic state.","Just added this MONDO term to the list, new curation from the Hereditary Cancer GCEP",,,,
BRCA1,HGNC:1100,"breast-ovarian cancer, familial, susceptibility to, 1",MONDO:0011450,AD,Yes,"The pathogenic mechanism for both hereditary breast cancer and Fanconi anemia is the same (loss-of-function), with single heterozygous variants causing breast cancer risk and biallelic variants causing Fanconi anemia. Therefore, P/LP variants that have been identified for either condition are reportable as SFs in the heterozygous or biallelic state.",,,,,
BRCA1,HGNC:1100,"Fanconi anemia, complementation group S",MONDO:0054748,AR,Yes,"The pathogenic mechanism for both hereditary breast cancer and Fanconi anemia is the same (loss-of-function), with single heterozygous variants causing breast cancer risk and biallelic variants causing Fanconi anemia. Therefore, P/LP variants that have been identified for either condition are reportable as SFs in the heterozygous or biallelic state.",,,,,
BRCA2,HGNC:1101,"breast-ovarian cancer, familial, susceptibility to, 2",MONDO:0012933,AD,Yes,"The pathogenic mechanism for both hereditary breast cancer and Fanconi anemia is the same (loss-of-function), with single heterozygous variants causing breast cancer risk and biallelic variants causing Fanconi anemia. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.",,,,,
BRCA2,HGNC:1101,Fanconi anemia complementation group D1,MONDO:0011584,AR,Yes,"The pathogenic mechanism for both hereditary breast cancer and Fanconi anemia is the same (loss-of-function), with single heterozygous variants causing breast cancer risk and biallelic variants causing Fanconi anemia. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.",,,,,
BRCA2,HGNC:1101,BRCA2-related cancer predisposition,MONDO:0700269,AD,Yes,"The pathogenic mechanism for both hereditary breast cancer and Fanconi anemia is the same (loss-of-function), with single heterozygous variants causing breast cancer risk and biallelic variants causing Fanconi anemia. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.","Just added this MONDO term to the list, new curation from the Hereditary Cancer GCEP",,,,
BTD,HGNC:1122,biotinidase deficiency,MONDO:0009665,AR,Yes,"BTD is only reportable if there are biallelic P/LP variants. If phase is unknown for two heterozygous P/LP variants, the variants are acceptable for return as SFs if the variants do not have prior evidence of existing in cis (on the same copy of the gene).",,,,,
BTD,HGNC:1122,Leigh syndrome,MONDO:0009723,AR,NA,"BTD is only reportable if there are biallelic P/LP variants. If phase is unknown for two heterozygous P/LP variants, the variants are acceptable for return as SFs if the variants do not have prior evidence of existing in cis (on the same copy of the gene).",,,,,
CACNA1S,HGNC:1397,"malignant hyperthermia, susceptibility to, 5",MONDO:0011163,AD,Yes,,,,,,
CACNA1S,HGNC:1397,malignant hyperthermia of anesthesia,MONDO:0018493,AD,Yes,,,,,,
CALM1,HGNC:1442,long QT syndrome,MONDO:0002442,AD,Yes,,,,,,
CALM1,HGNC:1442,catecholaminergic polymorphic ventricular tachycardia,MONDO:0017990,AD,Yes,,,,,,
CALM2,HGNC:1445,long QT syndrome,MONDO:0002442,AD,Yes,,,,,,
CALM2,HGNC:1445,catecholaminergic polymorphic ventricular tachycardia,MONDO:0017990,AD,Yes,,,,,,
CALM3,HGNC:1449,long QT syndrome,MONDO:0002442,AD,Yes,,,,,,
CALM3,HGNC:1449,catecholaminergic polymorphic ventricular tachycardia,MONDO:0017990,AD,Yes,,,,,,
CASQ2,HGNC:1513,catecholaminergic polymorphic ventricular tachycardia 2,MONDO:0012762,AR,Yes,"It is recommended that only P/LP variants associated to autosomal recessive CPVT be returned as SFs as the data supporting dominant inheritance of certain variants is not strong enough to support return as SFs. Also, CASQ2 is only reportable if there are biallelic P/LP variants. If phase is unknown for two heterozygous P/LP variants, the variants are acceptable for return as SFs if the variants do not have prior evidence of existing in cis (on the same copy of the gene).",,,,,
CASQ2,HGNC:1513,hypertrophic cardiomyopathy,MONDO:0005045,AD,NA,"It is recommended that only P/LP variants associated to autosomal recessive CPVT be returned as SFs as the data supporting dominant inheritance of certain variants is not strong enough to support return as SFs. Also, CASQ2 is only reportable if there are biallelic P/LP variants. If phase is unknown for two heterozygous P/LP variants, the variants are acceptable for return as SFs if the variants do not have prior evidence of existing in cis (on the same copy of the gene).",,,,,
CASQ2,HGNC:1513,catecholaminergic polymorphic ventricular tachycardia,MONDO:0017990,AR,Yes,"It is recommended that only P/LP variants associated to autosomal recessive CPVT be returned as SFs as the data supporting dominant inheritance of certain variants is not strong enough to support return as SFs. Also, CASQ2 is only reportable if there are biallelic P/LP variants. If phase is unknown for two heterozygous P/LP variants, the variants are acceptable for return as SFs if the variants do not have prior evidence of existing in cis (on the same copy of the gene).",,,,,
CASQ2,HGNC:1513,catecholaminergic polymorphic ventricular tachycardia,MONDO:0017990,AD,No,"It is recommended that only P/LP variants associated to autosomal recessive CPVT be returned as SFs as the data supporting dominant inheritance of certain variants is not strong enough to support return as SFs. Also, CASQ2 is only reportable if there are biallelic P/LP variants. If phase is unknown for two heterozygous P/LP variants, the variants are acceptable for return as SFs if the variants do not have prior evidence of existing in cis (on the same copy of the gene).",,,,,
COL3A1,HGNC:2201,"Ehlers-Danlos syndrome, vascular type",MONDO:0017314,AD,Yes,,,,,,
COL3A1,HGNC:2201,"autosomal dominant Ehlers-Danlos syndrome, vascular type",MONDO:0007524,AD,Yes,,,,,,
CYP27A1,HGNC:2605,cerebrotendinous xanthomatosis,MONDO:0008948,AR,Yes,"CYP27A1 is only reportable if there are biallelic P/LP variants. If phase is unknown for two heterozygous P/LP variants, the variants are acceptable for return as SFs if the variants do not have prior evidence of existing in cis (on the same copy of the gene).",,,,,
DES,HGNC:2770,arrhythmogenic right ventricular cardiomyopathy,MONDO:0016587,AD,Yes,,,,,,
DES,HGNC:2770,dilated cardiomyopathy,MONDO:0005021,AD,Yes,,,,,,
DES,HGNC:2770,myofibrillar myopathy 1,MONDO:0011076,,Yes,,,,,,
DSC2,HGNC:3036,familial isolated arrhythmogenic right ventricular dysplasia,MONDO:0016342,AD,Yes,,,,,,
DSC2,HGNC:3036,arrhythmogenic right ventricular dysplasia 11,MONDO:0012506,AD,Yes,,,,,,
DSG2,HGNC:3049,arrhythmogenic right ventricular cardiomyopathy,MONDO:0016587,AD,Yes,,,,,,
DSG2,HGNC:3049,arrhythmogenic right ventricular dysplasia 10,MONDO:0012434,AD,Yes,,,,,,
DSG2,HGNC:3049,dilated cardiomyopathy,MONDO:0005021,AD,NA,,,,,,
DSP,HGNC:3052,arrhythmogenic cardiomyopathy with wooly hair and keratoderma,MONDO:0011581,AD,Yes,,,,,,
DSP,HGNC:3052,dilated cardiomyopathy,MONDO:0005021,AD,Yes,,,,,,
DSP,HGNC:3052,hypertrophic cardiomyopathy,MONDO:0005045,AD,NA,,,,,,
ENG,HGNC:3349,"telangiectasia, hereditary hemorrhagic, type 1",MONDO:0008535,AD,Yes,,,,,,
ENG,HGNC:3349,juvenile polyposis syndrome,MONDO:0017380,AD,NA,,,,,,
FBN1,HGNC:3603,Marfan syndrome,MONDO:0007947,AD,Yes,,,,,,
FBN1,HGNC:3603,familial thoracic aortic aneurysm and aortic dissection,MONDO:0019625,AD,Yes,,,,,,
FBN1,HGNC:3603,Shprintzen-Goldberg syndrome,MONDO:0008426,AD,NA,,"Shprintzen-Goldberg syndrome is caused by pathogenic variants in SKI, not FBN1",,,,
FLNC,HGNC:3756,myofibrillar myopathy 5,MONDO:0012289,AD,Yes,,,,,,
FLNC,HGNC:3756,dilated cardiomyopathy,MONDO:0005021,AD,Yes,,,,,,
FLNC,HGNC:3756,myofibrillar myopathy,MONDO:0018943,AD,Yes,,,,,,
GAA,HGNC:4065,glycogen storage disease II,MONDO:0009290,AR,Yes,"GAA is only reportable if there are biallelic P/LP variants. If phase is unknown for two heterozygous P/LP variants, the variants are acceptable for return as SFs if the variants do not have prior evidence of existing in cis (on the same copy of the gene).",,,,,
GLA,HGNC:4296,Fabry disease,MONDO:0010526,XL,Yes,Heterozygous and homozygous P/LP variants in females as well as hemizygous in males are reportable.,,,,,
HFE,HGNC:4886,hemochromatosis type 1,MONDO:0021001,AR,Yes,Homozygous p.Cys282Tyr is the only reportable SF result.,,,,,
HFE,HGNC:4886,hereditary hemochromatosis,MONDO:0006507,,Yes,Homozygous p.Cys282Tyr is the only reportable SF result.,,,,,
HNF1A,HGNC:11621,monogenic diabetes,MONDO:0015967,AD,Yes,,,,,,
HNF1A,HGNC:11621,maturity-onset diabetes of the young type 3,MONDO:0010894,,Yes,,,,,,
HNF1A,HGNC:11621,maturity-onset diabetes of the young type 2,MONDO:0007453,,NA,,I don't see this one in ClinGen's curations. MODY2 is due to a different gene,,,,
KCNH2,HGNC:6251,Brugada syndrome,MONDO:0015263,AD,NA,,,,,,
KCNH2,HGNC:6251,long QT syndrome,MONDO:0002442,AD,Yes,,,,,,
KCNH2,HGNC:6251,short QT syndrome,MONDO:0000453,AD,Yes,,,,,,
KCNH2,HGNC:6251,long QT syndrome 2,MONDO:0013367,AD,Yes,,,,,,
KCNQ1,HGNC:6294,hypertrophic cardiomyopathy,MONDO:0005045,AD,NA,"Autosomal dominant longQT is due to pathogenic variants in KCNQ1, some of which act through a loss-of-function mechanism and others through a dominant negative gain-of-function mechanism. In contrast, autosomal recessive Jervell and Lange Nielson syndrome is due to pathogenic biallelic loss-of-function variants. P/LP variants implicated in either LQT or JLNS are reportable as SFs.",,,,,
KCNQ1,HGNC:6294,Jervell and Lange-Nielsen syndrome,MONDO:0002441,AR,Yes,"Autosomal dominant longQT is due to pathogenic variants in KCNQ1, some of which act through a loss-of-function mechanism and others through a dominant negative gain-of function mechanism. In contrast, autosomal recessive Jervell and Lange Nielson syndrome is due to pathogenic biallelic loss-of function variants. P/LP variants implicated in either LQT or JLNS are reportable as SFs.",,,,,
KCNQ1,HGNC:6294,long QT syndrome,MONDO:0002442,AD,Yes,"Autosomal dominant longQT is due to pathogenic variants in KCNQ1, some of which act through a loss-of-function mechanism and others through a dominant negative gain-of function mechanism. In contrast, autosomal recessive Jervell and Lange Nielson syndrome is due to pathogenic biallelic loss-of function variants. P/LP variants implicated in either LQT or JLNS are reportable as SFs.",,,,,
KCNQ1,HGNC:6294,short QT syndrome,MONDO:0000453,AD,Yes,"Autosomal dominant longQT is due to pathogenic variants in KCNQ1, some of which act through a loss-of-function mechanism and others through a dominant negative gain-of function mechanism. In contrast, autosomal recessive Jervell and Lange Nielson syndrome is due to pathogenic biallelic loss-of function variants. P/LP variants implicated in either LQT or JLNS are reportable as SFs.",,,,,
KCNQ1,HGNC:6294,long QT syndrome 1,MONDO:0100316,AD,Yes,"Autosomal dominant longQT is due to pathogenic variants in KCNQ1, some of which act through a loss-of-function mechanism and others through a dominant negative gain-of function mechanism. In contrast, autosomal recessive Jervell and Lange Nielson syndrome is due to pathogenic biallelic loss-of function variants. P/LP variants implicated in either LQT or JLNS are reportable as SFs.",,,,,
LDLR,HGNC:6547,"hypercholesterolemia, familial, 1",MONDO:0007750,SD,Yes,,,,,,
LMNA,HGNC:6636,arrhythmogenic right ventricular cardiomyopathy,MONDO:0016587,AD,NA,"P/LP LMNA variants that have any case level phenotype evidence of association with cardiac disease (eg, DCM, arrhythmogenic right ventricular cardiomyopathy, arrhythmogenic cardiomyopathy, and/or arrhythmia) should be reported as SFs, whereas previously reported P/LP missense variants never associated with cardiac disease should not be reported. Also, for novel pLOF variants that reach LP without case observations, these variants should be reported given the general association of pLOF LMNA variants with cardiac disease and the evidence summary should include mention of the spectrum of phenotypes that may be observed with LMNA pLOF variation.",,,,,
LMNA,HGNC:6636,dilated cardiomyopathy,MONDO:0005021,AD,Yes,"P/LP LMNA variants that have any case level phenotype evidence of association with cardiac disease (eg, DCM, arrhythmogenic right ventricular cardiomyopathy, arrhythmogenic cardiomyopathy, and/or arrhythmia) should be reported as SFs, whereas previously reported P/LP missense variants never associated with cardiac disease should not be reported. Also, for novel pLOF variants that reach LP without case observations, these variants should be reported given the general association of pLOF LMNA variants with cardiac disease and the evidence summary should include mention of the spectrum of phenotypes that may be observed with LMNA pLOF variation.",,,,,
LMNA,HGNC:6636,dilated cardiomyopathy 1A,MONDO:0007269,,Yes,"P/LP LMNA variants that have any case level phenotype evidence of association with cardiac disease (eg, DCM, arrhythmogenic right ventricular cardiomyopathy, arrhythmogenic cardiomyopathy, and/or arrhythmia) should be reported as SFs, whereas previously reported P/LP missense variants never associated with cardiac disease should not be reported. Also, for novel pLOF variants that reach LP without case observations, these variants should be reported given the general association of pLOF LMNA variants with cardiac disease and the evidence summary should include mention of the spectrum of phenotypes that may be observed with LMNA pLOF variation.",,,,,
LMNA,HGNC:6636,Emery-Dreifuss muscular dystrophy,MONDO:0016830,,Yes,"P/LP LMNA variants that have any case level phenotype evidence of association with cardiac disease (eg, DCM, arrhythmogenic right ventricular cardiomyopathy, arrhythmogenic cardiomyopathy, and/or arrhythmia) should be reported as SFs, whereas previously reported P/LP missense variants never associated with cardiac disease should not be reported. Also, for novel pLOF variants that reach LP without case observations, these variants should be reported given the general association of pLOF LMNA variants with cardiac disease and the evidence summary should include mention of the spectrum of phenotypes that may be observed with LMNA pLOF variation.",,,,,
LMNA,HGNC:6636,lipodystrophy,MONDO:0006573,SD,Pending,,,,,,
MAX,HGNC:6913,hereditary pheochromocytoma-paraganglioma,MONDO:0017366,AD,Yes,,,,,,
MAX,HGNC:6913,pheochromocytoma,MONDO:0008233,AD,Yes,,,,,,
MEN1,HGNC:7010,multiple endocrine neoplasia type 1,MONDO:0007540,AD,Yes,,,,,,
MLH1,HGNC:7127,mismatch repair cancer syndrome 1,MONDO:0010159,AR,Yes,"The pathogenic mechanism for both Lynch syndrome and mismatch repair cancer syndrome is the same (loss-of-function), with single heterozygous variants causing Lynch and biallelic variants causing mismatch repair cancer syndrome. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.",,,,,
MLH1,HGNC:7127,Lynch syndrome,MONDO:0005835,AD,Yes,"The pathogenic mechanism for both Lynch syndrome and mismatch repair cancer syndrome is the same (loss-of-function), with single heterozygous variants causing Lynch and biallelic variants causing mismatch repair cancer syndrome. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.",,,,,
MLH1,HGNC:7127,hereditary breast carcinoma,MONDO:0016419,AD,NA,"The pathogenic mechanism for both Lynch syndrome and mismatch repair cancer syndrome is the same (loss-of-function), with single heterozygous variants causing Lynch and biallelic variants causing mismatch repair cancer syndrome. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.",,,,,
MLH1,HGNC:7127,Lynch syndrome 2,MONDO:0012249,AD,Yes,"The pathogenic mechanism for both Lynch syndrome and mismatch repair cancer syndrome is the same (loss-of-function), with single heterozygous variants causing Lynch and biallelic variants causing mismatch repair cancer syndrome. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.",,,,,
MLH1,HGNC:7127,mismatch repair cancer syndrome,MONDO:0031219,AR,Yes,"The pathogenic mechanism for both Lynch syndrome and mismatch repair cancer syndrome is the same (loss-of-function), with single heterozygous variants causing Lynch and biallelic variants causing mismatch repair cancer syndrome. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.",,,,,
MSH2,HGNC:7325,mismatch repair cancer syndrome 1,MONDO:0010159,AR,Yes,"The pathogenic mechanism for both Lynch syndrome and mismatch repair cancer syndrome is the same (loss-of-function), with single heterozygous variants causing Lynch and biallelic variants causing mismatch repair cancer syndrome. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.",,,,,
MSH2,HGNC:7325,Lynch syndrome,MONDO:0005835,AD,Yes,"The pathogenic mechanism for both Lynch syndrome and mismatch repair cancer syndrome is the same (loss-of-function), with single heterozygous variants causing Lynch and biallelic variants causing mismatch repair cancer syndrome. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.",,,,,
MSH2,HGNC:7325,hereditary breast carcinoma,MONDO:0016419,AD,NA,"The pathogenic mechanism for both Lynch syndrome and mismatch repair cancer syndrome is the same (loss-of-function), with single heterozygous variants causing Lynch and biallelic variants causing mismatch repair cancer syndrome. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.",,,,,
MSH2,HGNC:7325,mismatch repair cancer syndrome,MONDO:0031219,AR,Yes,"The pathogenic mechanism for both Lynch syndrome and mismatch repair cancer syndrome is the same (loss-of-function), with single heterozygous variants causing Lynch and biallelic variants causing mismatch repair cancer syndrome. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.",,,,,
MSH6,HGNC:7329,mismatch repair cancer syndrome 1,MONDO:0010159,AR,Yes,"The pathogenic mechanism for both Lynch syndrome and mismatch repair cancer syndrome is the same (loss-of-function), with single heterozygous variants causing Lynch and biallelic variants causing mismatch repair cancer syndrome. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.",,,,,
MSH6,HGNC:7329,Lynch syndrome,MONDO:0005835,AD,Yes,"The pathogenic mechanism for both Lynch syndrome and mismatch repair cancer syndrome is the same (loss-of-function), with single heterozygous variants causing Lynch and biallelic variants causing mismatch repair cancer syndrome. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.",,,,,
MSH6,HGNC:7329,hereditary breast carcinoma,MONDO:0016419,AD,NA,"The pathogenic mechanism for both Lynch syndrome and mismatch repair cancer syndrome is the same (loss-of-function), with single heterozygous variants causing Lynch and biallelic variants causing mismatch repair cancer syndrome. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.",,,,,
MSH6,HGNC:7329,Lynch syndrome 5,MONDO:0013710,AD,Yes,"The pathogenic mechanism for both Lynch syndrome and mismatch repair cancer syndrome is the same (loss-of-function), with single heterozygous variants causing Lynch and biallelic variants causing mismatch repair cancer syndrome. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.",,,,,
MSH6,HGNC:7329,mismatch repair cancer syndrome,MONDO:0031219,AR,Yes,"The pathogenic mechanism for both Lynch syndrome and mismatch repair cancer syndrome is the same (loss-of-function), with single heterozygous variants causing Lynch and biallelic variants causing mismatch repair cancer syndrome. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.",,,,,
MUTYH,HGNC:7527,familial adenomatous polyposis 2,MONDO:0012041,AR,Yes,"MUTYH is only reportable if there are biallelic P/LP variants. If phase is unknown for two heterozygous P/LP variants, the variants are acceptable for return as SFs if the variants do not have prior evidence of existing in cis (on the same copy of the gene).",,,,,
MUTYH,HGNC:7527,familial ovarian cancer,MONDO:0016248,AR,NA,"MUTYH is only reportable if there are biallelic P/LP variants. If phase is unknown for two heterozygous P/LP variants, the variants are acceptable for return as SFs if the variants do not have prior evidence of existing in cis (on the same copy of the gene).",,,,,
MUTYH,HGNC:7527,hereditary breast carcinoma,MONDO:0016419,AR,NA,"MUTYH is only reportable if there are biallelic P/LP variants. If phase is unknown for two heterozygous P/LP variants, the variants are acceptable for return as SFs if the variants do not have prior evidence of existing in cis (on the same copy of the gene).",,,,,
MUTYH,HGNC:7527,colorectal cancer,MONDO:0005575,AD,NA,"MUTYH is only reportable if there are biallelic P/LP variants. If phase is unknown for two heterozygous P/LP variants, the variants are acceptable for return as SFs if the variants do not have prior evidence of existing in cis (on the same copy of the gene).",,,,,
MYBPC3,HGNC:7551,dilated cardiomyopathy,MONDO:0005021,AD,NA,,,,,,
MYBPC3,HGNC:7551,arrhythmogenic right ventricular cardiomyopathy,MONDO:0016587,AD,NA,,,,,,
MYBPC3,HGNC:7551,hypertrophic cardiomyopathy,MONDO:0005045,AD,Yes,,,,,,
MYBPC3,HGNC:7551,familial hypertrophic cardiomyopathy,MONDO:0024573,AD,Yes,,,,,,
MYBPC3,HGNC:7551,hypertrophic cardiomyopathy 4,MONDO:0007268,AD,Yes,,,,,,
MYBPC3,HGNC:7551,congenital heart disease,MONDO:0005453,AD,NA,,,,,,
MYH11,HGNC:7569,familial thoracic aortic aneurysm and aortic dissection,MONDO:0019625,AD,Yes,,,,,,
MYH11,HGNC:7569,congenital heart disease,MONDO:0005453,AD,NA,,,,,,
MYH7,HGNC:7577,arrhythmogenic right ventricular cardiomyopathy,MONDO:0016587,AD,NA,"Loss-of-function variants in MYH7 are NOT known to be associated with disease in the heterozygous state. Distinct pathogenic variants in MYH7 have been associated with hypertrophic cardiomyopathy, dilated cardiomyopathy and MYH7-related skeletal myopathy through different molecular mechanisms. Most HCM related variants are located in the head domain potentially affecting actin binding sites. DCM has been associated with variants that produce an abnormal protein with reduced function. Variants associated to skeletal myopathy are usually located in the rod domain and may be due to a dominant negative mechanism. Note: This text was summarized from ClinGen’s gene-disease validity evidence summaries for MYH7. https://search.clinicalgenome.org/kb/genes/HGNC:7577 The ACMG Secondary Findings working group recommends that P/LP variants associated with cardiomyopathy, but not skeletal myopathy be returned as SFs.",,,,,
MYH7,HGNC:7577,dilated cardiomyopathy,MONDO:0005021,AD,Yes,"Loss-of-function variants in MYH7 are NOT known to be associated with disease in the heterozygous state. Distinct pathogenic variants in MYH7 have been associated with hypertrophic cardiomyopathy, dilated cardiomyopathy and MYH7-related skeletal myopathy through different molecular mechanisms. Most HCM related variants are located in the head domain potentially affecting actin binding sites. DCM has been associated with variants that produce an abnormal protein with reduced function. Variants associated to skeletal myopathy are usually located in the rod domain and may be due to a dominant negative mechanism. Note: This text was summarized from ClinGen’s gene-disease validity evidence summaries for MYH7. https://search.clinicalgenome.org/kb/genes/HGNC:7577 The ACMG Secondary Findings working group recommends that P/LP variants associated with cardiomyopathy, but not skeletal myopathy be returned as SFs.",,,,,
MYH7,HGNC:7577,hypertrophic cardiomyopathy,MONDO:0005045,AD,Yes,"Loss-of-function variants in MYH7 are NOT known to be associated with disease in the heterozygous state. Distinct pathogenic variants in MYH7 have been associated with hypertrophic cardiomyopathy, dilated cardiomyopathy and MYH7-related skeletal myopathy through different molecular mechanisms. Most HCM related variants are located in the head domain potentially affecting actin binding sites. DCM has been associated with variants that produce an abnormal protein with reduced function. Variants associated to skeletal myopathy are usually located in the rod domain and may be due to a dominant negative mechanism. Note: This text was summarized from ClinGen’s gene-disease validity evidence summaries for MYH7. https://search.clinicalgenome.org/kb/genes/HGNC:7577 The ACMG Secondary Findings working group recommends that P/LP variants associated with cardiomyopathy, but not skeletal myopathy be returned as SFs.",,,,,
MYH7,HGNC:7577,MYH7-related skeletal myopathy,MONDO:0008050,AD,No,"Loss-of-function variants in MYH7 are NOT known to be associated with disease in the heterozygous state. Distinct pathogenic variants in MYH7 have been associated with hypertrophic cardiomyopathy, dilated cardiomyopathy and MYH7-related skeletal myopathy through different molecular mechanisms. Most HCM related variants are located in the head domain potentially affecting actin binding sites. DCM has been associated with variants that produce an abnormal protein with reduced function. Variants associated to skeletal myopathy are usually located in the rod domain and may be due to a dominant negative mechanism. Note: This text was summarized from ClinGen’s gene-disease validity evidence summaries for MYH7. https://search.clinicalgenome.org/kb/genes/HGNC:7577 The ACMG Secondary Findings working group recommends that P/LP variants associated with cardiomyopathy, but not skeletal myopathy be returned as SFs.",,,,,
MYH7,HGNC:7577,congenital heart disease,MONDO:0005453,AD,NA,"Loss-of-function variants in MYH7 are NOT known to be associated with disease in the heterozygous state. Distinct pathogenic variants in MYH7 have been associated with hypertrophic cardiomyopathy, dilated cardiomyopathy and MYH7-related skeletal myopathy through different molecular mechanisms. Most HCM related variants are located in the head domain potentially affecting actin binding sites. DCM has been associated with variants that produce an abnormal protein with reduced function. Variants associated to skeletal myopathy are usually located in the rod domain and may be due to a dominant negative mechanism. Note: This text was summarized from ClinGen’s gene-disease validity evidence summaries for MYH7. https://search.clinicalgenome.org/kb/genes/HGNC:7577 The ACMG Secondary Findings working group recommends that P/LP variants associated with cardiomyopathy, but not skeletal myopathy be returned as SFs.",,,,,
MYH7,HGNC:7577,familial hypertrophic cardiomyopathy,MONDO:0024573,AD,Yes,"Loss-of-function variants in MYH7 are NOT known to be associated with disease in the heterozygous state. Distinct pathogenic variants in MYH7 have been associated with hypertrophic cardiomyopathy, dilated cardiomyopathy and MYH7-related skeletal myopathy through different molecular mechanisms. Most HCM related variants are located in the head domain potentially affecting actin binding sites. DCM has been associated with variants that produce an abnormal protein with reduced function. Variants associated to skeletal myopathy are usually located in the rod domain and may be due to a dominant negative mechanism. Note: This text was summarized from ClinGen’s gene-disease validity evidence summaries for MYH7. https://search.clinicalgenome.org/kb/genes/HGNC:7577 The ACMG Secondary Findings working group recommends that P/LP variants associated with cardiomyopathy, but not skeletal myopathy be returned as SFs.",,,,,
MYH7,HGNC:7577,restrictive cardiomyopathy,MONDO:0005201,AD,Yes,"Loss-of-function variants in MYH7 are NOT known to be associated with disease in the heterozygous state. Distinct pathogenic variants in MYH7 have been associated with hypertrophic cardiomyopathy, dilated cardiomyopathy and MYH7-related skeletal myopathy through different molecular mechanisms. Most HCM related variants are located in the head domain potentially affecting actin binding sites. DCM has been associated with variants that produce an abnormal protein with reduced function. Variants associated to skeletal myopathy are usually located in the rod domain and may be due to a dominant negative mechanism. Note: This text was summarized from ClinGen’s gene-disease validity evidence summaries for MYH7. https://search.clinicalgenome.org/kb/genes/HGNC:7577 The ACMG Secondary Findings working group recommends that P/LP variants associated with cardiomyopathy, but not skeletal myopathy be returned as SFs.",,,,,
MYH7,HGNC:7577,cardiomyopathy,MONDO:0004994,AD,Yes,"Loss-of-function variants in MYH7 are NOT known to be associated with disease in the heterozygous state. Distinct pathogenic variants in MYH7 have been associated with hypertrophic cardiomyopathy, dilated cardiomyopathy and MYH7-related skeletal myopathy through different molecular mechanisms. Most HCM related variants are located in the head domain potentially affecting actin binding sites. DCM has been associated with variants that produce an abnormal protein with reduced function. Variants associated to skeletal myopathy are usually located in the rod domain and may be due to a dominant negative mechanism. Note: This text was summarized from ClinGen’s gene-disease validity evidence summaries for MYH7. https://search.clinicalgenome.org/kb/genes/HGNC:7577 The ACMG Secondary Findings working group recommends that P/LP variants associated with cardiomyopathy, but not skeletal myopathy be returned as SFs.",,,,,
MYH7,HGNC:7577,"congenital myopathy 7A, myosin storage, autosomal dominant",MONDO:0008409,AD,No,"Loss-of-function variants in MYH7 are NOT known to be associated with disease in the heterozygous state. Distinct pathogenic variants in MYH7 have been associated with hypertrophic cardiomyopathy, dilated cardiomyopathy and MYH7-related skeletal myopathy through different molecular mechanisms. Most HCM related variants are located in the head domain potentially affecting actin binding sites. DCM has been associated with variants that produce an abnormal protein with reduced function. Variants associated to skeletal myopathy are usually located in the rod domain and may be due to a dominant negative mechanism. Note: This text was summarized from ClinGen’s gene-disease validity evidence summaries for MYH7. https://search.clinicalgenome.org/kb/genes/HGNC:7577 The ACMG Secondary Findings working group recommends that P/LP variants associated with cardiomyopathy, but not skeletal myopathy be returned as SFs.",,,,,
MYH7,HGNC:7577,Ebstein anomaly,MONDO:0009144,,NA,"Loss-of-function variants in MYH7 are NOT known to be associated with disease in the heterozygous state. Distinct pathogenic variants in MYH7 have been associated with hypertrophic cardiomyopathy, dilated cardiomyopathy and MYH7-related skeletal myopathy through different molecular mechanisms. Most HCM related variants are located in the head domain potentially affecting actin binding sites. DCM has been associated with variants that produce an abnormal protein with reduced function. Variants associated to skeletal myopathy are usually located in the rod domain and may be due to a dominant negative mechanism. Note: This text was summarized from ClinGen’s gene-disease validity evidence summaries for MYH7. https://search.clinicalgenome.org/kb/genes/HGNC:7577 The ACMG Secondary Findings working group recommends that P/LP variants associated with cardiomyopathy, but not skeletal myopathy be returned as SFs.",,,,,
MYL2,HGNC:7583,hypertrophic cardiomyopathy 10,MONDO:0012112,AD,Yes,,,,,,
MYL2,HGNC:7583,arrhythmogenic right ventricular cardiomyopathy,MONDO:0016587,AD,NA,,,,,,
MYL2,HGNC:7583,dilated cardiomyopathy,MONDO:0005021,AD,NA,,,,,,
MYL2,HGNC:7583,hypertrophic cardiomyopathy,MONDO:0005045,AD,Yes,,,,,,
MYL2,HGNC:7583,familial hypertrophic cardiomyopathy,MONDO:0024573,AD,Yes,,,,,,
MYL3,HGNC:7584,arrhythmogenic right ventricular cardiomyopathy,MONDO:0016587,AD,NA,,,,,,
MYL3,HGNC:7584,dilated cardiomyopathy,MONDO:0005021,AD,NA,,,,,,
MYL3,HGNC:7584,hypertrophic cardiomyopathy,MONDO:0005045,AD,Yes,,,,,,
MYL3,HGNC:7584,familial hypertrophic cardiomyopathy,MONDO:0024573,AD,Yes,,,,,,
NF2,HGNC:7773,neurofibromatosis type 2,MONDO:0007039,AD,Yes,,,,,,
OTC,HGNC:8512,ornithine carbamoyltransferase deficiency,MONDO:0010703,XL,Yes,Heterozygous and homozygous P/LP variants in females as well as hemizygous in males are reportable.,,,,,
PALB2,HGNC:26144,Fanconi anemia complementation group N,MONDO:0012565,AR,Yes,"The pathogenic mechanism for both hereditary cancer and Fanconi anemia is the same (loss-of-function), with single heterozygous variants causing hereditary cancer and biallelic variants causing Fanconi anemia. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.",,,,,
PALB2,HGNC:26144,hereditary nonpolyposis colon cancer,MONDO:0018630,AD,NA,"The pathogenic mechanism for both hereditary cancer and Fanconi anemia is the same (loss-of-function), with single heterozygous variants causing hereditary cancer and biallelic variants causing Fanconi anemia. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.",,,,,
PALB2,HGNC:26144,hereditary breast carcinoma,MONDO:0016419,AD,Yes,"The pathogenic mechanism for both hereditary cancer and Fanconi anemia is the same (loss-of-function), with single heterozygous variants causing hereditary cancer and biallelic variants causing Fanconi anemia. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.",,,,,
PALB2,HGNC:26144,familial ovarian cancer,MONDO:0016248,AD,Yes,"The pathogenic mechanism for both hereditary cancer and Fanconi anemia is the same (loss-of-function), with single heterozygous variants causing hereditary cancer and biallelic variants causing Fanconi anemia. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.",,,,,
PALB2,HGNC:26144,PALB2-related cancer predisposition,MONDO:0700272,AD,Yes,"The pathogenic mechanism for both hereditary cancer and Fanconi anemia is the same (loss-of-function), with single heterozygous variants causing hereditary cancer and biallelic variants causing Fanconi anemia. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.",,,,,
PCSK9,HGNC:20001,"hypercholesterolemia, autosomal dominant, 3",MONDO:0011369,AD,Yes,The mechanism of pathogenicity for hypercholesterolemia is gain-of-function variants. LOF variants should not be reported as SFs as they are associated with low levels of LDL cholesterol.,,,,,
PKP2,HGNC:9024,arrhythmogenic right ventricular cardiomyopathy,MONDO:0016587,AD,Yes,,,,,,
PKP2,HGNC:9024,arrhythmogenic right ventricular dysplasia 9,MONDO:0012180,AD,Yes,,,,,,
PKP2,HGNC:9024,Brugada syndrome 1,MONDO:0011001,AD,NA,,,,,,
PKP2,HGNC:9024,dilated cardiomyopathy,MONDO:0005021,AD,NA,,,,,,
PKP2,HGNC:9024,catecholaminergic polymorphic ventricular tachycardia,MONDO:0017990,AD,NA,,,,,,
PLN,HGNC:9080,intrinsic cardiomyopathy,MONDO:0000591,AD,Yes,"The typical inheritance for PLN related cardiomyopathy is autosomal dominant, albeit autosomal recessive inheritance has been noted and appears to follow a dosage effect or semidominance, as loss of both alleles results in an earlier and more severe phenotypic presentation (PMID: 12639993). Missense, pLOF and promoter variants have all been reported as pathogenic. Given that PLN only has one exon, most variants, including pLOFs, result in a protein product. There is no observed difference in molecular mechanism(s) underlying the various forms of cardiomyopathy including dilated, hypertrophic and arrhythmogenic right ventricular cardiomyopathy. Both interfamilial and intrafamilial variability are observed between PLN variants (PMID: 12639993, 22820313). Therefore, all of the disease entities have been lumped into one disease entity, Intrinsic cardiomyopathy. There is a relatively common Dutch founder pathogenic variant NM_002667.5 c.37AGA[1] (p.Arg14del) that may be present in up to 10-15% of patients with DCM or ARVC in the Netherlands. Note, this information was summarized from ClinGen's gene-disease validity evidence summaries for PLN: https://search.clinicalgenome.org/kb/genes/HGNC:9080",,,,,
PLN,HGNC:9080,arrhythmogenic right ventricular cardiomyopathy,MONDO:0016587,AD,Yes,"The typical inheritance for PLN related cardiomyopathy is autosomal dominant, albeit autosomal recessive inheritance has been noted and appears to follow a dosage effect or semidominance, as loss of both alleles results in an earlier and more severe phenotypic presentation (PMID: 12639993). Missense, pLOF and promoter variants have all been reported as pathogenic. Given that PLN only has one exon, most variants, including pLOFs, result in a protein product. There is no observed difference in molecular mechanism(s) underlying the various forms of cardiomyopathy including dilated, hypertrophic and arrhythmogenic right ventricular cardiomyopathy. Both interfamilial and intrafamilial variability are observed between PLN variants (PMID: 12639993, 22820313). Therefore, all of the disease entities have been lumped into one disease entity, Intrinsic cardiomyopathy. There is a relatively common Dutch founder pathogenic variant NM_002667.5 c.37AGA[1] (p.Arg14del) that may be present in up to 10-15% of patients with DCM or ARVC in the Netherlands. Note, this information was summarized from ClinGen's gene-disease validity evidence summaries for PLN: https://search.clinicalgenome.org/kb/genes/HGNC:9080",,,,,
PMS2,HGNC:9122,mismatch repair cancer syndrome 1,MONDO:0010159,AR,Yes,"The pathogenic mechanism for both Lynch syndrome and mismatch repair cancer syndrome is the same (loss-of-function), with single heterozygous variants causing Lynch and biallelic variants causing mismatch repair cancer syndrome. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.",,,,,
PMS2,HGNC:9122,Lynch syndrome,MONDO:0005835,AD,Yes,"The pathogenic mechanism for both Lynch syndrome and mismatch repair cancer syndrome is the same (loss-of-function), with single heterozygous variants causing Lynch and biallelic variants causing mismatch repair cancer syndrome. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.",,,,,
PMS2,HGNC:9122,hereditary breast carcinoma,MONDO:0016419,AD,NA,"The pathogenic mechanism for both Lynch syndrome and mismatch repair cancer syndrome is the same (loss-of-function), with single heterozygous variants causing Lynch and biallelic variants causing mismatch repair cancer syndrome. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.",,,,,
PMS2,HGNC:9122,Lynch syndrome 4,MONDO:0013699,AD,Yes,"The pathogenic mechanism for both Lynch syndrome and mismatch repair cancer syndrome is the same (loss-of-function), with single heterozygous variants causing Lynch and biallelic variants causing mismatch repair cancer syndrome. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.",,,,,
PMS2,HGNC:9122,mismatch repair cancer syndrome,MONDO:0031219,AR,Yes,"The pathogenic mechanism for both Lynch syndrome and mismatch repair cancer syndrome is the same (loss-of-function), with single heterozygous variants causing Lynch and biallelic variants causing mismatch repair cancer syndrome. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.",,,,,
PRKAG2,HGNC:9386,hypertrophic cardiomyopathy,MONDO:0005045,AD,Yes,,,,,,
PRKAG2,HGNC:9386,PRKAG2-related cardiomyopathy,MONDO:0800484,AD,Yes,,,,,,
PRKAG2,HGNC:9386,familial hypertrophic cardiomyopathy,MONDO:0024573,AD,Yes,,,,,,
PTEN,HGNC:9588,PTEN hamartoma tumor syndrome,MONDO:0017623,AD,Yes,,,,,,
PTEN,HGNC:9588,multiple exostoses with spastic tetraparesis,MONDO:0008020,,NA,,,,,,
RB1,HGNC:9884,retinoblastoma,MONDO:0008380,AD,Yes,,,,,,
RB1,HGNC:9884,hereditary retinoblastoma,MONDO:0018160,AD,Yes,,,,,,
RBM20,HGNC:27424,dilated cardiomyopathy,MONDO:0005021,AD,Yes,,,,,,
RBM20,HGNC:27424,hypertrophic cardiomyopathy,MONDO:0005045,AD,NA,,,,,,
RET,HGNC:9967,multiple endocrine neoplasia type 2A,MONDO:0008234,AD,Yes,The mechanism of pathogenicity for multiple endocrine neoplasia is gain-of-function. LOF variants should not be reported as SFs.,,,,,
RET,HGNC:9967,multiple endocrine neoplasia type 2B,MONDO:0008082,AD,Yes,The mechanism of pathogenicity for multiple endocrine neoplasia is gain-of-function. LOF variants should not be reported as SFs.,,,,,
RET,HGNC:9967,familial medullary thyroid carcinoma,MONDO:0007958,AD,Yes,The mechanism of pathogenicity for multiple endocrine neoplasia is gain-of-function. LOF variants should not be reported as SFs.,,,,,
RET,HGNC:9967,"Hirschsprung disease, susceptibility to, 1",MONDO:0007723,AR,No,The mechanism of pathogenicity for multiple endocrine neoplasia is gain-of-function. LOF variants should not be reported as SFs.,,,,,
RPE65,HGNC:10294,RPE65-related recessive retinopathy,MONDO:0100368,AR,Yes,"Only variants associated with autosomal recessive disease are suggested for SF return by the ACMG SF working group. There is currently only one valid dominant pathogenic variant and individuals with this variant are not eligible for gene therapy and therefore this variant is not recommended for return as a SF at this time. Also, RPE65 is only reportable if there are biallelic P/LP variants. If phase is unknown for two heterozygous P/LP variants, the variants are acceptable for return if the variants do not have prior evidence of existing in cis (on the same copy of the gene).",,,,,
RPE65,HGNC:10294,RPE65-related dominant retinopathy,MONDO:0100452,AD,No,"Only variants associated with autosomal recessive disease are suggested for SF return by the ACMG SF working group. There is currently only one valid dominant pathogenic variant and individuals with this variant are not eligible for gene therapy and therefore this variant is not recommended for return as a SF at this time. Also, RPE65 is only reportable if there are biallelic P/LP variants. If phase is unknown for two heterozygous P/LP variants, the variants are acceptable for return if the variants do not have prior evidence of existing in cis (on the same copy of the gene).",,,,,
RPE65,HGNC:10294,Leber congenital amaurosis 2,MONDO:0008765,,Yes,"Only variants associated with autosomal recessive disease are suggested for SF return by the ACMG SF working group. There is currently only one valid dominant pathogenic variant and individuals with this variant are not eligible for gene therapy and therefore this variant is not recommended for return as a SF at this time. Also, RPE65 is only reportable if there are biallelic P/LP variants. If phase is unknown for two heterozygous P/LP variants, the variants are acceptable for return if the variants do not have prior evidence of existing in cis (on the same copy of the gene).",,,,,
RYR1,HGNC:10483,RYR1-related myopathy,MONDO:0100150,AR,No,P/LP variants in RYR1 can be associated with either malignant hyperthermia or a neuromuscular phenotype. Only P/LP variants associated with malignant hyperthermia should be reported as SFs.,,,,,
RYR1,HGNC:10483,RYR1-related myopathy,MONDO:0100150,AD,No,P/LP variants in RYR1 can be associated with either malignant hyperthermia or a neuromuscular phenotype. Only P/LP variants associated with malignant hyperthermia should be reported as SFs.,,,,,
RYR1,HGNC:10483,"malignant hyperthermia, susceptibility to, 1",MONDO:0007783,AD,Yes,P/LP variants in RYR1 can be associated with either malignant hyperthermia or a neuromuscular phenotype. Only P/LP variants associated with malignant hyperthermia should be reported as SFs.,,,,,
RYR1,HGNC:10483,malignant hyperthermia of anesthesia,MONDO:0018493,AD,Yes,P/LP variants in RYR1 can be associated with either malignant hyperthermia or a neuromuscular phenotype. Only P/LP variants associated with malignant hyperthermia should be reported as SFs.,,,,,
RYR2,HGNC:10484,catecholaminergic polymorphic ventricular tachycardia,MONDO:0017990,AD,Yes,,,,,,
RYR2,HGNC:10484,catecholaminergic polymorphic ventricular tachycardia 1,MONDO:0011484,AD,Yes,,,,,,
RYR2,HGNC:10484,hypertrophic cardiomyopathy,MONDO:0005045,AD,NA,,,,,,
RYR2,HGNC:10484,arrhythmogenic right ventricular cardiomyopathy,MONDO:0016587,AD,NA,,,,,,
SCN5A,HGNC:10593,familial long QT syndrome,MONDO:0019171,AD,Yes,,,,,,
SCN5A,HGNC:10593,Brugada syndrome,MONDO:0015263,AD,Yes,,,,,,
SCN5A,HGNC:10593,Brugada syndrome 1,MONDO:0011001,AD,Yes,,,,,,
SCN5A,HGNC:10593,dilated cardiomyopathy,MONDO:0005021,AD,Yes,,,,,,
SCN5A,HGNC:10593,catecholaminergic polymorphic ventricular tachycardia,MONDO:0017990,AD,NA,,,,,,
SCN5A,HGNC:10593,arrhythmogenic right ventricular cardiomyopathy,MONDO:0016587,AD,NA,,,,,,
SCN5A,HGNC:10593,short QT syndrome,MONDO:0000453,AD,NA,,,,,,
SCN5A,HGNC:10593,congenital heart disease,MONDO:0005453,AD,NA,,,,,,
SDHAF2,HGNC:26034,hereditary pheochromocytoma-paraganglioma,MONDO:0017366,AD,Yes,,,,,,
SDHB,HGNC:10681,hereditary pheochromocytoma-paraganglioma,MONDO:0017366,AD,Yes,,,,,,
SDHB,HGNC:10681,mitochondrial disease,MONDO:0044970,AR,No,,,,,,
SDHC,HGNC:10682,hereditary pheochromocytoma-paraganglioma,MONDO:0017366,AD,Yes,,,,,,
SDHC,HGNC:10682,mitochondrial disease,MONDO:0044970,Other,NA,,,,,,
SDHC,HGNC:10682,paragangliomas 3,MONDO:0011544,AD,Yes,,,,,,
SDHD,HGNC:10683,hereditary pheochromocytoma-paraganglioma,MONDO:0017366,AD,Yes,,,,,,
SDHD,HGNC:10683,mitochondrial disease,MONDO:0044970,AR,NA,,,,,,
SDHD,HGNC:10683,paragangliomas 1,MONDO:0008192,AD,Yes,,,,,,
SMAD3,HGNC:6769,aneurysm-osteoarthritis syndrome,MONDO:0013426,AD,Yes,,,,,,
SMAD3,HGNC:6769,familial thoracic aortic aneurysm and aortic dissection,MONDO:0019625,AD,Yes,,,,,,
SMAD3,HGNC:6769,Loeys-Dietz syndrome,MONDO:0018954,AD,Yes,,,,,,
SMAD4,HGNC:6770,juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome,MONDO:0008278,AD,Yes,"P/LP variants in SMAD4 are linked to juvenile polyposis with hereditary hemorrhagic telangiectasia (JP/HHT) syndrome, juvenile intestinal polyposis syndrome (JPS), and Myhre syndrome. P/LP variants causal for JP/HHT and JPS are due to heterozygous loss-of-function variants and are reportable as SF results. Myhre syndrome, a multi-system disorder involving intellectual disability, is caused by one of four SMAD4 missense variants [c.1498A>G (p.Ile500Val); c.1499T>C (p.Ile500Thr); c.1500A>G (p.Ile500Met), and c.1486C>T (p.Arg496Cys)] and is not on the list of reportable diseases. Variants for Myhre syndrome should not be returned.",,,,,
SMAD4,HGNC:6770,Myhre syndrome,MONDO:0007688,AD,No,"P/LP variants in SMAD4 are linked to juvenile polyposis with hereditary hemorrhagic telangiectasia (JP/HHT) syndrome, juvenile intestinal polyposis syndrome (JPS), and Myhre syndrome. P/LP variants causal for JP/HHT and JPS are due to heterozygous loss-of-function variants and are reportable as SF results. Myhre syndrome, a multi-system disorder involving intellectual disability, is caused by one of four SMAD4 missense variants [c.1498A>G (p.Ile500Val); c.1499T>C (p.Ile500Thr); c.1500A>G (p.Ile500Met), and c.1486C>T (p.Arg496Cys)] and is not on the list of reportable diseases. Variants for Myhre syndrome should not be returned.",,,,,
SMAD4,HGNC:6770,pulmonary arterial hypertension,MONDO:0015924,AD,NA,"P/LP variants in SMAD4 are linked to juvenile polyposis with hereditary hemorrhagic telangiectasia (JP/HHT) syndrome, juvenile intestinal polyposis syndrome (JPS), and Myhre syndrome. P/LP variants causal for JP/HHT and JPS are due to heterozygous loss-of-function variants and are reportable as SF results. Myhre syndrome, a multi-system disorder involving intellectual disability, is caused by one of four SMAD4 missense variants [c.1498A>G (p.Ile500Val); c.1499T>C (p.Ile500Thr); c.1500A>G (p.Ile500Met), and c.1486C>T (p.Arg496Cys)] and is not on the list of reportable diseases. Variants for Myhre syndrome should not be returned.",,,,,
SMAD4,HGNC:6770,juvenile polyposis syndrome,MONDO:0017380,,Yes,"P/LP variants in SMAD4 are linked to juvenile polyposis with hereditary hemorrhagic telangiectasia (JP/HHT) syndrome, juvenile intestinal polyposis syndrome (JPS), and Myhre syndrome. P/LP variants causal for JP/HHT and JPS are due to heterozygous loss-of-function variants and are reportable as SF results. Myhre syndrome, a multi-system disorder involving intellectual disability, is caused by one of four SMAD4 missense variants [c.1498A>G (p.Ile500Val); c.1499T>C (p.Ile500Thr); c.1500A>G (p.Ile500Met), and c.1486C>T (p.Arg496Cys)] and is not on the list of reportable diseases. Variants for Myhre syndrome should not be returned.",,,,,
STK11,HGNC:11389,familial ovarian cancer,MONDO:0016248,AD,NA,,,,,,
STK11,HGNC:11389,Peutz-Jeghers syndrome,MONDO:0008280,AD,Yes,,,,,,
TGFBR1,HGNC:11772,Loeys-Dietz syndrome,MONDO:0018954,AD,Yes,"Missense variants in the intracellular kinase domain of TGFBR1 are known to cause Loeys-Dietz syndrome with unclear molecular mechanism which could include gain-of-function and dominant negative. These variants are returnable as SFs. In contrast, truncating variants or missense variants in the receptor domain of TGFBR1 cause multiple self-healing squamous epithelioma (MSSE; OMIM 132800) with loss-of-function mechanism and are not returnable as SFs.",,,,,
TGFBR1,HGNC:11772,multiple self-healing squamous epithelioma,MONDO:0007566,AD,No,"Missense variants in the intracellular kinase domain of TGFBR1 are known to cause Loeys-Dietz syndrome with unclear molecular mechanism which could include gain-of-function and dominant negative. These variants are returnable as SFs. In contrast, truncating variants or missense variants in the receptor domain of TGFBR1 cause multiple self-healing squamous epithelioma (MSSE; OMIM 132800) with loss-of-function mechanism and are not returnable as SFs.",,,,,
TGFBR1,HGNC:11772,familial thoracic aortic aneurysm and aortic dissection,MONDO:0019625,AD,Yes,"Missense variants in the intracellular kinase domain of TGFBR1 are known to cause Loeys-Dietz syndrome with unclear molecular mechanism which could include gain-of-function and dominant negative. These variants are returnable as SFs. In contrast, truncating variants or missense variants in the receptor domain of TGFBR1 cause multiple self-healing squamous epithelioma (MSSE; OMIM 132800) with loss-of-function mechanism and are not returnable as SFs.",,,,,
TGFBR2,HGNC:11773,familial thoracic aortic aneurysm and aortic dissection,MONDO:0019625,AD,Yes,,,,,,
TGFBR2,HGNC:11773,Loeys-Dietz syndrome 2,MONDO:0012427,AD,Yes,,,,,,
TGFBR2,HGNC:11773,Loeys-Dietz syndrome,MONDO:0018954,,Yes,,,,,,
TMEM127,HGNC:26038,hereditary pheochromocytoma-paraganglioma,MONDO:0017366,AD,Yes,,,,,,
TMEM43,HGNC:28472,arrhythmogenic right ventricular dysplasia 5,MONDO:0011459,AD,Yes,,,,,,
TNNC1,HGNC:11943,arrhythmogenic right ventricular cardiomyopathy,MONDO:0016587,AD,NA,,,,,,
TNNC1,HGNC:11943,hypertrophic cardiomyopathy,MONDO:0005045,AD,Yes,,,,,,
TNNC1,HGNC:11943,dilated cardiomyopathy,MONDO:0005021,AD,Yes,,,,,,
TNNI3,HGNC:11947,arrhythmogenic right ventricular cardiomyopathy,MONDO:0016587,AD,NA,,,,,,
TNNI3,HGNC:11947,dilated cardiomyopathy,MONDO:0005021,AD,Yes,,,,,,
TNNI3,HGNC:11947,hypertrophic cardiomyopathy,MONDO:0005045,AD,Yes,,,,,,
TNNI3,HGNC:11947,familial hypertrophic cardiomyopathy,MONDO:0024573,,Yes,,,,,,
TNNI3,HGNC:11947,"cardiomyopathy, familial restrictive, 1",MONDO:0007270,,Yes,,,,,,
TNNT2,HGNC:11949,arrhythmogenic right ventricular cardiomyopathy,MONDO:0016587,AD,NA,,,,,,
TNNT2,HGNC:11949,dilated cardiomyopathy,MONDO:0005021,AD,Yes,,,,,,
TNNT2,HGNC:11949,hypertrophic cardiomyopathy,MONDO:0005045,AD,Yes,,,,,,
TNNT2,HGNC:11949,familial hypertrophic cardiomyopathy,MONDO:0024573,AD,Yes,,,,,,
TP53,HGNC:11998,Li-Fraumeni syndrome,MONDO:0018875,AD,Yes,,,,,,
TP53,HGNC:11998,Li-Fraumeni syndrome 1,MONDO:0007903,,Yes,,,,,,
TPM1,HGNC:12010,arrhythmogenic right ventricular cardiomyopathy,MONDO:0016587,AD,NA,,,,,,
TPM1,HGNC:12010,dilated cardiomyopathy,MONDO:0005021,AD,Yes,,,,,,
TPM1,HGNC:12010,hypertrophic cardiomyopathy,MONDO:0005045,AD,Yes,,,,,,
TPM1,HGNC:12010,familial hypertrophic cardiomyopathy,MONDO:0024573,,Yes,,,,,,
TRDN,HGNC:12261,catecholaminergic polymorphic ventricular tachycardia,MONDO:0017990,AR,Yes,"The MANE Select transcript, NM_006073.4, which has 41 exons, is not the relevant transcript for cardiac disease reporting. Variants should only be reported in exons 1-8 of NM_001256021.1, the predominant transcript in cardiac tissue. Also, TRDN is only reportable if there are biallelic P/LP variants. If phase is unknown for two heterozygous P/LP variants, the variants are acceptable for return if the variants do not have prior evidence of existing in cis (on the same copy of the gene).",,,,,
TRDN,HGNC:12261,catecholaminergic polymorphic ventricular tachycardia 5,MONDO:0014191,,Yes,"The MANE Select transcript, NM_006073.4, which has 41 exons, is not the relevant transcript for cardiac disease reporting. Variants should only be reported in exons 1-8 of NM_001256021.1, the predominant transcript in cardiac tissue. Also, TRDN is only reportable if there are biallelic P/LP variants. If phase is unknown for two heterozygous P/LP variants, the variants are acceptable for return if the variants do not have prior evidence of existing in cis (on the same copy of the gene).",,,,,
TRDN,HGNC:12261,long QT syndrome,MONDO:0002442,AR,Yes,"The MANE Select transcript, NM_006073.4, which has 41 exons, is not the relevant transcript for cardiac disease reporting. Variants should only be reported in exons 1-8 of NM_001256021.1, the predominant transcript in cardiac tissue. Also, TRDN is only reportable if there are biallelic P/LP variants. If phase is unknown for two heterozygous P/LP variants, the variants are acceptable for return if the variants do not have prior evidence of existing in cis (on the same copy of the gene).",,,,,
TSC1,HGNC:12362,tuberous sclerosis,MONDO:0001734,AD,Yes,,,,,,
TSC1,HGNC:12362,tuberous sclerosis 1,MONDO:0008612,,Yes,,,,,,
TSC2,HGNC:12363,tuberous sclerosis,MONDO:0001734,AD,Yes,,,,,,
TSC2,HGNC:12363,tuberous sclerosis 2,MONDO:0013199,,Yes,,,,,,
TTN,HGNC:12403,dilated cardiomyopathy,MONDO:0005021,AD,Yes,"Frameshift, nonsense, and splice-impacting variants in TTN exons with high PSI (see references PMCID: PMC4560092; PMC5201198; http://cardiodb.org/titin) should be evaluated for pathogenicity and returned as SFs if classified as P/LP for dilated cardiomyopathy. Distinct pathogenic variants are associated with different forms of both AD and AR muscle disease (see ClinGen GCEP reports) and are not recommended for return as SFs.",,,,,
TTN,HGNC:12403,hypertrophic cardiomyopathy,MONDO:0005045,AD,NA,"Frameshift, nonsense, and splice-impacting variants in TTN exons with high PSI (see references PMCID: PMC4560092; PMC5201198; http://cardiodb.org/titin) should be evaluated for pathogenicity and returned as SFs if classified as P/LP for dilated cardiomyopathy. Distinct pathogenic variants are associated with different forms of both AD and AR muscle disease (see ClinGen GCEP reports) and are not recommended for return as SFs.",,,,,
TTN,HGNC:12403,arrhythmogenic right ventricular cardiomyopathy,MONDO:0016587,AD,NA,"Frameshift, nonsense, and splice-impacting variants in TTN exons with high PSI (see references PMCID: PMC4560092; PMC5201198; http://cardiodb.org/titin) should be evaluated for pathogenicity and returned as SFs if classified as P/LP for dilated cardiomyopathy. Distinct pathogenic variants are associated with different forms of both AD and AR muscle disease (see ClinGen GCEP reports) and are not recommended for return as SFs.",,,,,
TTN,HGNC:12403,tibial muscular dystrophy,MONDO:0010870,AD,No,"Frameshift, nonsense, and splice-impacting variants in TTN exons with high PSI (see references PMCID: PMC4560092; PMC5201198; http://cardiodb.org/titin) should be evaluated for pathogenicity and returned as SFs if classified as P/LP for dilated cardiomyopathy. Distinct pathogenic variants are associated with different forms of both AD and AR muscle disease (see ClinGen GCEP reports) and are not recommended for return as SFs.",,,,,
TTN,HGNC:12403,"myopathy, myofibrillar, 9, with early respiratory failure",MONDO:0011362,AD,No,"Frameshift, nonsense, and splice-impacting variants in TTN exons with high PSI (see references PMCID: PMC4560092; PMC5201198; http://cardiodb.org/titin) should be evaluated for pathogenicity and returned as SFs if classified as P/LP for dilated cardiomyopathy. Distinct pathogenic variants are associated with different forms of both AD and AR muscle disease (see ClinGen GCEP reports) and are not recommended for return as SFs.",,,,,
TTN,HGNC:12403,TTN-related myopathy,MONDO:0100175,AR,No,"Frameshift, nonsense, and splice-impacting variants in TTN exons with high PSI (see references PMCID: PMC4560092; PMC5201198; http://cardiodb.org/titin) should be evaluated for pathogenicity and returned as SFs if classified as P/LP for dilated cardiomyopathy. Distinct pathogenic variants are associated with different forms of both AD and AR muscle disease (see ClinGen GCEP reports) and are not recommended for return as SFs.",,,,,
TTN,HGNC:12403,dilated cardiomyopathy 1G,MONDO:0011400,,Yes,"Frameshift, nonsense, and splice-impacting variants in TTN exons with high PSI (see references PMCID: PMC4560092; PMC5201198; http://cardiodb.org/titin) should be evaluated for pathogenicity and returned as SFs if classified as P/LP for dilated cardiomyopathy. Distinct pathogenic variants are associated with different forms of both AD and AR muscle disease (see ClinGen GCEP reports) and are not recommended for return as SFs.",,,,,
TTR,HGNC:12405,obsolete hereditary ATTR amyloidosis,MONDO:0017132,AD,Yes,,,,,,
TTR,HGNC:12405,familial amyloid neuropathy,MONDO:0007100,,Yes,,,,,,
VHL,HGNC:12687,von Hippel-Lindau disease,MONDO:0008667,AD,Yes,,,,,,
WT1,HGNC:12796,Wilms tumor 1,MONDO:0008679,AD,Yes,,,,,,
WT1,HGNC:12796,Denys-Drash syndrome,MONDO:0008682,AD,Pending,,,,,,